A historic long-term agreement between World Anti-Doping Agency (WADA) and GlaxoSmithKline (GSK), one of the world's leading research-based pharmaceutical and healthcare companies will help future athletes a great deal. Under the agreement, GSK will help WADA create early detection methods for medicines that have performance-enhancing potential in sport.
The historic partnership will see GSK supply WADA with confidential information about medicines in early stage development that could be abused by athletes once they are licensed for appropriate patient use. Read more...
